A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking study is presented in a Hot Line at the European Society of Cardiology (ESC) 2021 Congress, and was published in the New England Journal of Medicine. Data from the EMPEROR-Preserved and in EMPEROR-Reduced trials.
October 04, 2021
Empagliflozin Benefits Heart Failure Patients With Reduced and Preserved Ejection Fraction
October 1, 2021 — A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin…
Read More
October 04, 2021
ESC Issues Guidelines on Cardiac Pacing and Cardiac Resynchronization Therapy
October 1, 2021 — The European Society of Cardiology (ESC) guidelines on cardiac pacing and cardiac resynchronization…
Read More
MASTER DAPT Shows 1-month Dual Antiplatelet Therapy After Stent Benefits High Bleeding Risk Patients, DAPT. #ESCCongress
October 04, 2021
MASTER DAPT Shows 1-month Dual Antiplatelet Therapy After Stent Benefits High Bleeding Risk Patients
October 4, 2021 —  One month of dual antiplatelet therapy (DAPT) following stent implantation in high bleeding risk…
Read More
A cardiac scan on the new Siemens Naeotom Alpha. This is the first commercialized photon-counting CT scanner. It gained FDA clearance Sept. 30, 2021. Image by Deutscher Zukunftpreis/Ansgar Pudenz.
By Dave Fornell, DAIC Editor
October 04, 2021
First Photon-counting CT System Cleared by the FDA
The U.S. Food and Drug Administration (FDA) Sept. 30 cleared the world's first photon-counting computed tomography (CT…
Read More
Gadolinium-enhanced MRI of a cardiac radiation therapy patient at baseline (left) and 3 months post-treatment (right). Top: the left ventricle with patchy, gadolinium-enhanced scar was transmurally targeted with a radiation ose of 25 Gy between 3 and 6 o’clock (red brackets). Nonenhanced, remote myocardium is adjacent to target region (white arrowhead). Bottom: surviving nonenhanced myocardium within the same images is visible in the targeted region at baseline and 3 months post-treatment (yellow outline).
September 28, 2021
Radiation Therapy Reprograms Heart Cells to Younger State
September 28, 2021 — New research from Washington University School of Medicine in St. Louis suggests that radiation…
Read More
Biotricity Inc., a medical diagnostic and consumer healthcare technology company, has developed a personal medical device kit, Biokit, that includes a bundled of home-use devices to monitor cardiovascular disease. It includes a digital thermometer, a pulse oximeter and a blood pressure cuff. All three devices are U.S. FDA cleared, wireless, wearable, and integrate into the Biotricity ecosystem, a platform for interconnectivity. 
September 28, 2021
Biotricity Releases Biokit With Three Home Monitoring Devices for Cardiac Disease Management
September 28, 2021 — Biotricity Inc., a medical diagnostic and consumer healthcare technology company, has developed a…
Read More
CardioMEMS is a wireless, battery-free sensor that is implanted into the pulmonary artery via a right heart catheterization procedure to transmit pulmonary artery pressures.
September 28, 2021
GUIDE-HF Trial Shows Hemodynamic Guided Management Benefits Larger Heart Failure Population
September 28, 2021 — Hemodynamic guided management using the CardioMEMS device may reduce heart failure…
Read More
COVID Long-hauler Symptoms May be Caused by Antibody Attacks on ACE2
September 28, 2021
COVID Long-hauler Symptoms May be Caused by Antibody Attacks on ACE2
September 28, 2021 — A research team at the University of Arkansas for Medical Sciences (UAMS) has identified a…
Read More
High-resolution 3-D delayed enhancement MRI of the left atrium can be used for quantification of fibrosis based on relative intensity of contrast enhancement The DECAAF study found this may help determine which patients will benefit from fibrosis ablation combined with PVI, and which ones are best served with the PVI.
September 28, 2021
Fibrosis Ablation Shows Promise in AFib With Low Grade Fibrotic Myopathy
September 28, 2021 — Image-guided fibrosis ablation in addition to pulmonary vein isolation (PVI) does not improve…
Read More
Zebra Medical Vision now offers artificial intelligence (A) medical imaging analytics for its cardiac solution HealthCCSng, which enables the quantification of the coronary artery calcium (CAC) on CT scans as an incidental finding. Zebra gained FDA clearance for the product in September 2021.
September 27, 2021
FDA Clears Zebra Coronary Artery Calcium Solution as Part of Its Population Health Offering
September 27, 2021 — Zebra Medical Vision, the deep-learning medical imaging analytics company, announces its eighth U.…
Read More
Illustration of the Watchman transcatheter left atrial appendage (LAA) occluder being  deployed into the LAA. FDA is concerned about higher rates of LAA occlusion complications in women compared to men, prompting the FDA to send a letter to providers warning them on possible poor outcomes.
September 27, 2021
FDA Concerned About Higher Rates of LAA Occlusion Complications in Women
September 27, 2021 — Compared with men undergoing left atrial appendage occlusion (LAAO), women have a significantly…
Read More
Test selection should be a shared decision between patient and physician rather than directed by insurers’ test substitution policies, according to a statement published online in the Journal of the American College of Cardiology.[1] The statement summarizes the proceedings of a recent summit convened by the American Society of Nuclear Cardiology (ASNC), leadership of the American College of Cardiology Imaging Council, American Society of Echocardiography (ASE), Society of Cardiovascular Computed Tomography
September 22, 2021
Cardiovascular Imaging Organizations Denounce Test Substitution by Insurance Companies
September 22, 2021 — Test selection should be a shared decision between patient and physician rather than directed by…
Read More
Cardiothoracic surgeons with UofL Health – Jewish Hospital and the University of Louisville performed the world’s first Carmat Aeson bioprosthetic total artificial heart implantation in a female patient on Sept. 14, 2021. The device was small enough to fit into the woman's smaller chest cavity. The device is being tested as a bridge to heart transplant rather than use of a LVAD. Photo by UofL Health.
September 22, 2021
First Woman in World Receives New Type of Artificial Heart 
September 22, 2021 — A cardiothoracic surgical team with University of Louisville Health – Jewish Hospital has…
Read More
ESC Releases Guidelines on Heart Failure Management
September 21, 2021
ESC Releases Guidelines on Heart Failure Management
September 21, 2021 — The European Society of Cardiology (ESC) Guidelines for the diagnosis and treatment of acute and…
Read More
Medtronic is recalling its Pipeline Flex Embolization Device and Pipeline Flex Embolization Device with Shield Technology, which are transcatheter devices used to seal brain aneurysms. The company said there is a risk of the delivery system’s wire and tubes fracturing and breaking off when the system is being used to place, retrieve, or move the stent inside a patient.
September 21, 2021
Medtronic Recalls Neurovascular Pipeline Flex Embolization Devices for Risk of Fractures During Placement, Retrieval or Movement of Device
September 21, 2021 — Medtronic is recalling its Pipeline Flex Embolization Device and Pipeline Flex Embolization Device…
Read More
The U.S. Food and Drug Administration (FDA) has cleared the company's Portico with FlexNav transcatheter aortic valve replacement (TAVR) system to treat people with symptomatic, severe aortic stenosis who are at high or extreme risk for open-heart surgery. 
By Dave Fornell, Editor
September 20, 2021
FDA Clears Abbott Portico TAVR System to Treat Aortic Valve Disease
September 20, 2021 — Abbott announced that the U.S. Food and Drug Administration (FDA) has cleared the company's…
Read More
A rise in coronavirus, COVID-19, has prompted the American Heart Association (AHA) to cancel plans for an in-person, annual meeting in November and again host a virtual meeting instead. Getty images #AHA21 #AHA
September 20, 2021
American Heart Association Cancels In-Person Meeting and Goes Virtual Again Due to COVID
September 20, 2021 — The American Heart Association (AHA) announced Sept. 16 it decided to convert from a planned in-…
Read More
By Aaron Detate and Lars Thording
September 14, 2021
The Growing Need for Reprocessing in the Cardiac Cath Lab
In the electrophysiology (EP) lab, hundreds of thousands of used devices are sent to reprocessors every year to get…
Read More
Us2.ai has received U.S. Food and Drug Administration (FDA) clearance for its artificial intelligence (AI) Us2.v1 software, a completely automated decision support tool for echocardiography.
September 14, 2021
FDA Clears Fully Automated Cardiac Ultrasound Solution to Measure 2D and Doppler
September 14, 2021 – Us2.ai, a Singapore-based medtech firm backed by Sequoia India and EDBI, has received U.S. Food…
Read More
MedAxiom conducetd a survey of hospitals that offer cardiac rehab, cardiovascular rehabilitation, programs to find out the costs, how they are staffed and how they are implemented.
September 14, 2021
MedAxiom Survey Highlights Cardiac Rehab Industry Insights and Best Practices
September 14, 2021 – MedAxiom, an American College of Cardiology (ACC) company, released a report detailing cardiac…
Read More
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now